• V5 Epitope Tag Peptide: Optimizing Protein Tagging Workflows

  2026-05-21

  The V5 Epitope Tag Peptide streamlines recombinant protein detection and purification across diverse experimental platforms, standing out for its compatibility with rapid antibody screening and advanced imaging. Explore protocol tips, troubleshooting, and the impact of fast-dissociating antibodies for next-generation protein tagging.

• DOT1L Inhibition Enhances Innate Immunity in Multiple Myelom

  2026-05-21

  This study demonstrates that DOT1L inhibition reprograms innate immune signaling and amplifies the efficacy of immunomodulatory drugs in multiple myeloma. The findings reveal a central epigenetic vulnerability in MM and characterize the molecular pathways through which DOT1L inhibition exerts anti-tumor effects, informing future translational research and therapeutic strategies.

• Degarelix Acetate: Molecular Insights for Advanced Prostate

  2026-05-20

  Explore the deep molecular mechanisms of Degarelix acetate, a potent GnRH receptor antagonist, and discover how advanced synthesis and receptor specificity drive innovation in prostate cancer research. Gain practical assay guidance and new perspectives that go beyond standard workflows.

• nor-Binaltorphimine dihydrochloride: Circuit-Level Insights

  2026-05-20

  Explore how nor-Binaltorphimine dihydrochloride, a potent κ-opioid receptor antagonist, enables advanced dissection of neural circuits underlying pain. This article offers in-depth, assay-focused guidance for opioid receptor signaling research, distinct from scenario-based protocols.

• Bortezomib (PS-341): Proteasome Inhibition and Apoptosis Red

  2026-05-19

  This thought-leadership article explores how Bortezomib (PS-341) is reshaping our mechanistic understanding of proteasome inhibition and apoptosis, weaving in recent discoveries on RNA Pol II-mediated cell death. Translational researchers gain actionable insights on deploying Bortezomib in advanced apoptosis assays, benchmarking protocols, and positioning their work at the cutting edge of oncology and cell death research.

• Angiotensin II–HIF-1α-HILPDA Axis Drives Radioresistance in

  2026-05-19

  This study uncovers how local angiotensin II suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma (NPC) via the HIF-1α-HILPDA axis. The results highlight a feedback loop linking the tumor microenvironment to impaired radiotherapy response, with actionable implications for radiosensitization strategies.

• GOT1 Inhibition by Ziprasidone Reprograms Redox in PDAC

  2026-05-18

  Yang et al. (2022) identify ziprasidone as a non-competitive inhibitor of GOT1, disrupting glutamine metabolism and redox balance in pancreatic ductal adenocarcinoma (PDAC) cells. Their work highlights metabolic targeting of GOT1 as a promising strategy for impeding tumor growth and provides mechanistic evidence for exploiting tumor redox vulnerabilities in cancer research.

• Abiraterone acetate (SKU A8202): Reliable CYP17 Inhibitor Wo

  2026-05-18

  This article guides life science researchers through real-world challenges in prostate cancer research, focusing on reproducible experimental design, data interpretation, and reliable sourcing of Abiraterone acetate (SKU A8202). Scenario-driven Q&A blocks, grounded in peer-reviewed evidence and robust product specifications, showcase how this CYP17 inhibitor enhances cellular assay consistency and translational insight.

• Butylated Hydroxyanisole (BHA): Applied Redox Strategies in

  2026-05-17

  Butylated hydroxyanisole (BHA) from APExBIO delivers unmatched precision in oxidative stress research, enabling robust modulation of reactive oxygen species (ROS) and apoptosis pathways. This guide demystifies practical experimental workflows and troubleshooting approaches to maximize reproducibility and performance with BHA in advanced disease modeling.

• Amyloid Beta-Peptide (1-40) (human): Advanced Workflows for

  2026-05-16

  Amyloid Beta-Peptide (1-40) (human) from APExBIO empowers precise modeling of amyloid aggregation and neurotoxicity, uniquely supporting both mechanistic studies and translational applications in Alzheimer’s disease research. Explore advanced workflows, troubleshooting tactics, and insights from recent discoveries that redefine how this peptide informs neurodegeneration studies.

• In Vitro Susceptibility of Staphylococci to Mupirocin and No

  2026-05-15

  This study evaluates the in vitro activity of mupirocin and novobiocin against meticillin-resistant and meticillin-susceptible staphylococci from dogs, highlighting key resistance trends and methodology. Its findings inform antimicrobial selection for veterinary dermatology and provide a comparative framework for in vitro antibacterial testing strategies.

• Merimepodib (VX-497): Precision IMPDH Inhibition in Antivira

  2026-05-15

  Merimepodib (VX-497) empowers researchers to selectively target guanine nucleotide biosynthesis, delivering robust inhibition of cell proliferation and viral replication. With validated, cross-species efficacy and unique workflow flexibility, it unlocks new possibilities for cancer, immunology, and virology experiments—especially where specificity and reversibility are critical.

• N3-kethoxal: Precision Mapping of RNA Structures and Genomic

  2026-05-14

  N3-kethoxal, a membrane-permeable azide-functionalized nucleic acid probe, enables high-resolution, covalent labeling of unpaired guanine bases in both RNA and DNA for advanced structural and functional genomic studies. Its versatility spans in vitro and live-cell assays, supporting cutting-edge applications from RNA secondary structure probing to direct mapping of accessible genomic DNA. This article provides proven workflows, troubleshooting strategies, and evidence-based protocol parameters to maximize assay reliability and reproducibility.

• Paclitaxel (Taxol): Defining Selectivity and Potency in Canc

  2026-05-14

  Explore how Paclitaxel (Taxol) delivers unmatched selectivity and potency in cancer research, with a unique focus on assay precision and translational impact. Discover how its mechanistic clarity and validated parameters set the gold standard for experimental design.

• Autophagy–Metastasis Prognostic Signature in Colorectal Canc

  2026-05-13

  Bai et al. (2026) developed and validated a prognostic signature comprising six genes related to autophagy and liver metastasis in colorectal cancer. Integrating bulk and single-cell transcriptomics, this signature predicts clinical outcomes, immune microenvironment remodeling, and potential therapeutic resistance, advancing precision oncology for CRC patients.

15634 records 1/1043 page Next 12345 下5页 Last page